 Connection
Anthony Elias to Prognosis
This is a "connection" page, showing publications Anthony Elias has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.369 |
|
|
|
-
Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol. 2010 Dec; 33(6):637-45.
Score: 0.053
-
Bowles DW, Rabinovitch R, Borges V, Urquhart A, Singh M, Finlayson C, Elias A. A young woman with a small ER-positive breast cancer, a micrometastatic axillary lymph node, and an intermediate oncotype DX recurrence score. Oncology (Williston Park). 2007 Sep; 21(10):1212-7.
Score: 0.043
-
Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant. 2002; 8(4):198-205.
Score: 0.029
-
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663.
Score: 0.029
-
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5.
Score: 0.028
-
Brechbuhl HM, Vinod-Paul K, Gillen AE, Kopin EG, Gibney K, Elias AD, Hayashi M, Sartorius CA, Kabos P. Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells. Mol Carcinog. 2020 10; 59(10):1129-1139.
Score: 0.026
-
Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest. 1997 Oct; 112(4 Suppl):251S-258S.
Score: 0.021
-
Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol. 2018 Mar; 25(3):768-775.
Score: 0.021
-
Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? J Natl Compr Canc Netw. 2017 04; 15(4):494-503.
Score: 0.021
-
Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E, Elias A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol. 1995 Aug; 13(8):2043-9.
Score: 0.018
-
Fisher CM, Klein CE, Kondapalli LA, Elias AD, Borges VF. Management of young breast cancer patients with de novo genetic mutations. Oncology (Williston Park). 2014 Oct; 28(10):895-6.
Score: 0.017
-
Elias AD. Advances in the diagnosis and management of sarcomas. Curr Opin Oncol. 1990 Jun; 2(3):474-80.
Score: 0.013
-
Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF. Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. Oncology (Williston Park). 2009 Aug; 23(9):784-91.
Score: 0.012
-
Elias AD, Antman KH. Adjuvant chemotherapy for soft-tissue sarcoma: a critical appraisal. Semin Surg Oncol. 1988; 4(1):59-65.
Score: 0.011
-
Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF. Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000; 6(5):476-95.
Score: 0.006
-
Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997 Jun; 3(2):98-106.
Score: 0.005
-
Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol. 1993 Jun; 11(6):1085-91.
Score: 0.004
-
Lynch TJ, Kass F, Kalish LA, Elias AD, Strauss G, Shulman LN, Sugarbaker DJ, Skarin A, Frei E. Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer. Cancer. 1993 May 15; 71(10):2953-7.
Score: 0.004
-
Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990 Oct; 8(10):1699-706.
Score: 0.003
-
Morris SW, Daniel L, Ahmed CM, Elias A, Lebowitz P. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood. 1990 May 15; 75(10):2035-41.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|